Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols

International Journal of Urology

Volumn 21, Issue 4, 2014, Pages 377-381

  Kim, Tae Heon ^a   Jeon, Hwang Gyun ^a   Choo, Seol Ho ^a   Jeong, Byong Chang ^a   Seo, Seong Il ^a   Jeon, Seong Soo ^a   Choi, Han Yong ^a   Lee, Hyun Moo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Active surveillance; Clinical protocols; Insignificant; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE CANCER SURVEILLANCE; AGED; ARTICLE; BLOOD LEVEL; CANADA; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; JOHNS HOPKINS CRITERION; MAJOR CLINICAL STUDY; MALE; MEMORIAL SLOAN KETTERING CANCER CENTER CRITERION; MIAMI CRITERION; PRIORITY JOURNAL; PROSPECTIVE PROSTATE CANCER RESEARCH INTERNATIONAL ACTIVE SURVEILLANCE CRITERION; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; SEMINAL VESICLE; TORONTO CRITERION; TRANSRECTAL ULTRASOUND GUIDED BIOPSY; TUMOR VOLUME; UNITED STATES; UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO CRITERION; ADJUVANT THERAPY; ASIAN CONTINENTAL ANCESTRY GROUP; HEALTH SURVEY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; SOUTH KOREA;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; POPULATION SURVEILLANCE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPUBLIC OF KOREA;

EID: 84898057543     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12326     Document Type: Article

References (25)

1. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol. Oncol. 2006; 24: 465-471.
2. Adamy A, Yee DS, Matsushita K etal. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J. Urol. 2011; 185: 477-482.
3. Dall'Era MA, Konety BR, Cowan JE etal. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112: 2664-2670.
4. Klotz L, Zhang L, Lam A, Nam R, Mamedoy A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 2010; 28: 126-131.
5. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur. Urol. 2010; 58: 831-835.
6. Tosoian JJ, Trock BJ, Landis P etal. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 2011; 29: 2185-2190.
7. van den Bergh RC, Roemeling S, Roobol MJ etal. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur. Urol. 2009; 55: 1-8.
8. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J. Urol. 2009; 181: 1628-1633.
9. Louie-Johnsun M, Neill M, Treurnicht K, Jarmulowicz M, Eden C. Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically. BJU Int. 2009; 104: 1501-1504.
10. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology 2010; 76: 689-692.
11. Jung KW, Park S, Kong HJ etal. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res. Treat. 2012; 44: 11-24.
12. Byun SS, Lee S, Lee SE etal. Recent changes in the clinicopathologic features of Korean men with prostate cancer: a comparison with Western populations. Yonsei Med. J. 2012; 53: 543-549.
13. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am. J. Surg. Pathol. 1988; 12: 897-906.
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
15. Lu-Yao GL, Albertsen PC, Moore DF etal. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-1209.
16. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol. 2007; 178: S14-19.
17. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur. Urol. 2012; 62: 462-468.
18. Capitanio U, Karakiewicz PI, Jeldres C etal. The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. Int. J. Urol. 2009; 16: 526-529.
19. Kim D, Choi D, Lim JH etal. Changes in prostate cancer aggressiveness over a 12-year period in Korea. Korean J. Urol. 2012; 53: 680-685.
20. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results. J. Urol. 2004; 172: 910-914.
21. van Houten ME, Gooren LJ. Differences in reproductive endocrinology between Asian men and Caucasian men-a literature review. Asian J. Androl. 2000; 2: 13-20.
22. Lee SE, Kim DS, Lee WK etal. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int. 2010; 105: 1526-1530.
23. Capitanio U, Karakiewicz PI, Valiquette L etal. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009; 73: 1087-1091.
24. Ploussard G, Xylinas E, Salomon L etal. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur. Urol. 2009; 56: 891-898.
25. Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int. 2009; 103: 43-48.